Reuters logo
2 months ago
BRIEF-Mithra Pharmaceuticals receives orphan drug designation from EMA for E4 in neonatal encephalopathy‍​
June 9, 2017 / 6:15 AM / 2 months ago

BRIEF-Mithra Pharmaceuticals receives orphan drug designation from EMA for E4 in neonatal encephalopathy‍​

June 9 (Reuters) - MITHRA PHARMACEUTICALS SA:

* RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR E4 IN NEONATAL ENCEPHALOPATHY‍​

* EVIDENCE OF POTENTIAL OF E4 TO ADDRESS ADDITIONAL INDICATIONS BEYOND WOMEN’S HEALTH Source text: bit.ly/2s2sb76 Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below